The ASsessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Network is an epidemiological study of long term outcomes following episodes of AKI. The AKI Network includes Clinical Research Centers at Kaiser Permanente of Northern California, Vanderbilt University - Validation of Acute Lung Injury Biomarkers for Diagnosis (VALID) Study, and Translational Research Investigating Biomarker End-Points (TRIBE) consortium (Yale University, University of Cincinnati, University of London, Ontario, McGill University, Montreal) and a Data Coordinating Center at Penn State University. The overall goals of ASSESS-AKI are to make significant contributions to the field of AKI in the five following areas:
- Establishing a diverse prospective parallel, matched cohort of adults and children with and without AKI.
- Characterizing the short-term and long-term natural history of AKI based on current serum creatinine-based criteria.
- Evaluating the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI.
- Developing a prognostic risk score that integrates patient characteristics and biomarkers to help inform providers and patients about the risks of adverse events after an episode of AKI.
- Identifying the subset of high-risk patients with AKI who could be targeted for future interventional clinical trials to improve outcomes after an episode of AKI.
The ASSESS-AKI Study will address the following Specific Aims through the initiation and follow-up of a long-term prospective cohort of patients with and without evidence of AKI:
- Aim 1 — To determine whether persons who survive an episode of AKI have a greater risk of developing chronic kidney disease or faster progression of pre-existing chronic kidney disease than hospitalized persons without AKI after accounting for pre-existing level of kidney function and potential confounders.
- Aim 2 — To determine whether persons who suffer from an episode of AKI have a higher risk of death, cardiovascular events, and other adverse events after hospital discharge than matched persons who did not suffer AKI during hospitalization, after accounting for pre-existing level of kidney function and potential confounders.
- Aim 3 — To evaluate the incremental value of serial measurements of several different blood and urine biomarkers for predicting short- and long-term clinical outcomes after an episode of AKI currently defined using a serum creatinine-based criteria.
- Aim 4 — To assess whether severity and type of the AKI episode and the presence of pre-existing chronic kidney disease influence long-term risks of loss of kidney function, death, and cardiovascular events in persons with AKI.
- Aim 5 — To determine if persons who completely recover kidney function within three months of an episode of AKI have a lower risk of adverse events than those persons with AKI whose recovery is incomplete.
- Aim 6 — To develop a risk score incorporating demographic features, clinical factors, and/or biomarkers that accurately predicts outcomes after an episode of AKI.
- Go AS, Parikh CR, Ikizler TA, Coca S, Siew ED, Chinchilli VM, Hsu CY, Garg AX, Zappitelli M, Liu KD, Reeves WB, Ghahramani N, Devarajan P, Faulkner GB, Tan TC, Kimmel PL, Eggers P, Stokes JB, Assessment Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury Study Investigators.: The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol. 2010 Aug 27; 2010 Aug 27. PMID: 20799966